A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Liver Cancer

A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Hepatocellular Carcinoma

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00563095

Enrollment

100

Registered

2007-11-26

Start date

2004-03-31

Completion date

2008-12-31

Last updated

2010-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Hepatocellular

Keywords

Hepatocellular carcinoma

Brief summary

Primary: To compare the efficacy of TACE and TAIE. Secondary: To compare the side effects of TACE and TAIE. The outcome measurements include survival benefit and tumour regression induced by the two therapies.

Interventions

PROCEDURETranscatheter Arterial Chemoembolization (TACE)

PROCEDURETranscatheter Arterial Pegylated Interferon Embolization (TAIE)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Confirmed hepatocellular carcinoma not suitable for surgery

Exclusion criteria

* Portal vein thrombosis * Severe arteriovenous shunt * Bilirubin level \> 50 umol/mL * Prothrombin time \> 5 seconds

Design outcomes

Primary

Measure	Time frame
regression of tumour size	assessment every 6 months

Secondary

Measure	Time frame
side effects	every treatment given every 8 - 12 weeks

Countries

China

Contacts

Primary ContactMan Fung Yuen, Prof

mfyuen@hkucc.hku.hk(852) 2855 5311

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026